Role of Fidaxomicin in a Patient Population With Problematic Clostridium Difficile Infection

Trial Profile

Role of Fidaxomicin in a Patient Population With Problematic Clostridium Difficile Infection

Discontinued
Phase of Trial: Phase IV

Latest Information Update: 18 Oct 2016

At a glance

  • Drugs Fidaxomicin (Primary) ; Vancomycin
  • Indications Clostridium infections
  • Focus Therapeutic Use
  • Most Recent Events

    • 12 Oct 2016 Status changed from recruiting to discontinued.
    • 29 Sep 2016 Planned End Date changed from 1 Mar 2016 to 1 Mar 2017.
    • 29 Sep 2016 Planned primary completion date changed from 1 Feb 2016 to 1 Feb 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top